Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2015 pubmed 37 citations

Overexpressions of hBD-2, hBD-3, and hCAP18/LL-37 in Gingiva of Diabetics with Periodontitis.

Yılmaz. Dogukan D; Güncü. Guliz N GN; Könönen. Eija E; Barış. Emre E; Çağlayan. Feriha F; Gursoy. Ulvi Kahraman UK

Key Findings

  • LL‑37, hBD‑2, and hBD‑3 are significantly elevated in gingiva of diabetics with periodontitis (p≈0.005‑0.002).
  • In healthy gums, hBD‑2 is found in superficial layers while hBD‑3 and LL‑37 are in basal layers; disease spreads them across all layers.
  • No significant difference in peptide levels between non‑diabetic periodontitis patients and healthy controls.

Practical Outcomes

  • The study suggests that diabetic gum disease is linked to altered antimicrobial peptide activity, highlighting the importance of tight blood‑sugar control and rigorous oral hygiene. It does not provide a new supplement or dosage recommendation for LL‑37, but underscores that simply boosting LL‑37 may not be beneficial without addressing underlying diabetes‑related inflammation.

Summary

People with type‑2 diabetes and gum disease have higher levels of the natural antimicrobial proteins hBD‑2, hBD‑3 and LL‑37 in their gum tissue compared to healthy people. The proteins are spread throughout the gum lining instead of being confined to specific layers, which may reflect a disturbed immune response in diabetics.

Abstract

Antimicrobial peptides of the epithelium play a significant role in the innate immune response in the oral cavity, which is constantly exposed to microbes. Type 2 diabetes mellitus (T2DM) is a highly prevalent metabolic disease which is related to periodontal disease. To date, little is known about expressions of antimicrobial peptides in gingival epithelia of diabetics. Our aim was to examine the expression and localization of human beta-defensins (hBD)-2 and -3 and cathelicidin (hCAP18/LL-37) in diabetic subjects suffering from generalized periodontitis (GP). Gingival tissue sections were collected from three subject groups: 14 T2DM subjects with GP (T2DM+GP), 11 systemically healthy GP patients (GP), and 13 systemically and periodontally healthy subjects (control). Surgical incisions targeted the sulcular epithelium and/or the bottom of the selected periodontal pocket. Tissue specimens were fixed in paraformaldehyde and embedded in paraffin blocks. Immunohistochemistry stainings were performed for cytokeratin19, hBD-2, hBD-3 and hCAP18/LL-37. Stainings were examined under light microscope with 40× magnification. Results were statistically evaluated by the t-test. In controls, hBD-2 was localized at the superficial layers of the gingival epithelium, hBD-3 and hCAP18/LL-37 were at the basal layers, whereas in subjects with periodontitis both defensins were visible at all epithelial layers. hBD-2 was detected in the nucleus and cytoplasm, while hBD-3 and hCAP18/LL-37 were detected only in the cytoplasm of the cells. Expressions of hBD-2 (p=0.005), hBD-3 (p=0.007), and hCAP18/LL-37 (p=0.002) were elevated in subjects with T2DM+GP in comparison to controls. No statistically significant difference was found in the expression of hBD-2, -3, and hCAP18/LL-37 between the GP group and the control or T2DM+GP groups. Gingival antimicrobial peptides are overexpressed in T2DM. This outcome can be part of impaired immune response in diabetics, and underlying factors and mechanisms need to be elucidated.

Study Information

Provider

pubmed

Year

2015

Date

2015-06-10T00:00:00.000Z

DOI

10.1016/j.imbio.2015.06.013

Citations

37

References

50